These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25392352)

  • 41. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.
    Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskov A; Ramani R
    J Clin Microbiol; 2008 Jul; 46(7):2155-9. PubMed ID: 18463213
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp.
    Peterson JF; Pfaller MA; Diekema DJ; Rinaldi MG; Riebe KM; Ledeboer NA
    J Clin Microbiol; 2011 May; 49(5):1765-71. PubMed ID: 21430096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome.
    Paredes K; Pastor FJ; Capilla J; Sutton DA; Mayayo E; Fothergill AW; Guarro J
    Rev Iberoam Micol; 2015; 32(1):34-9. PubMed ID: 24594291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
    Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
    Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species.
    Ramírez M; Serrano MC; Castro C; López E; Almeida C; Fernández A; Romero A; Martín-Mazuelos E
    J Antimicrob Chemother; 2006 Oct; 58(4):861-3. PubMed ID: 16916868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey.
    Pemán J; Cantón E; Quindós G; Eraso E; Alcoba J; Guinea J; Merino P; Ruiz-Pérez-de-Pipaon MT; Pérez-del-Molino L; Linares-Sicilia MJ; Marco F; García J; Roselló EM; Gómez-G-de-la-Pedrosa E; Borrell N; Porras A; Yagüe G;
    J Antimicrob Chemother; 2012 May; 67(5):1181-7. PubMed ID: 22351683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates.
    Metin DY; Hilmioglu-Polat S; Samlioglu P; Doganay-Oflazoglu B; Inci R; Tumbay E
    Mycopathologia; 2011 Sep; 172(3):187-99. PubMed ID: 21424603
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Agreement of Direct Antifungal Susceptibility Testing from Positive Blood Culture Bottles with the Conventional Method for Candida Species.
    Jabeen K; Kumar H; Farooqi J; Mehboob R; Brandt ME; Zafar A
    J Clin Microbiol; 2016 Feb; 54(2):343-8. PubMed ID: 26607985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Susceptibility testing of Prototheca bovis isolates from cases of bovine mastitis using the CLSI reference broth microdilution method and the Sensititre YeastOne colorimetric panel.
    Álvarez-Pérez S; Anega B; Díaz-de-Tuesta JA; González-Martín JV; Riesgo-Martínez M; García ME; Blanco JL
    Med Mycol; 2021 Dec; 59(12):1257-1261. PubMed ID: 34643716
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of two commercial methods for the susceptibility testing of Candida species: Vitek 2
    Siqueira RA; Doi AM; de Petrus Crossara PP; Koga PCM; Marques AG; Nunes FG; Pasternak J; Martino MDV
    Rev Iberoam Micol; 2018; 35(2):83-87. PubMed ID: 29580699
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Distribution and antifungal susceptibility of Candida species causing nosocomial candiduria.
    Ozhak-Baysan B; Ogunc D; Colak D; Ongut G; Donmez L; Vural T; Gunseren F
    Med Mycol; 2012 Jul; 50(5):529-32. PubMed ID: 21988703
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital.
    Miranda-Zapico I; Eraso E; Hernández-Almaraz JL; López-Soria LM; Carrillo-Muñoz AJ; Hernández-Molina JM; Quindós G
    J Antimicrob Chemother; 2011 Oct; 66(10):2315-22. PubMed ID: 21795259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods.
    Pfaller MA; Watanabe N; Castanheira M; Messer SA; Jones RN
    J Antimicrob Chemother; 2011 Nov; 66(11):2581-4. PubMed ID: 21873291
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Antifungal susceptibility of Candida spp. isolates from blood cultures in a five-year period (1997-2001)].
    Durán MT; Velasco D; Canle D; Moure R; Villanueva R
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):488-92. PubMed ID: 14572381
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.
    Pfaller MA; Messer SA; Mills K; Bolmström A; Jones RN
    J Clin Microbiol; 2001 Nov; 39(11):3952-4. PubMed ID: 11682513
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp.
    Espinel-Ingroff A; Pfaller M; Messer SA; Knapp CC; Holliday N; Killian SB
    J Clin Microbiol; 2004 Feb; 42(2):718-21. PubMed ID: 14766842
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Quindós G; Miranda-Cadena K; San-Millán R; Borroto-Esoda K; Cantón E; Linares-Sicilia MJ; Hamprecht A; Montesinos I; Tortorano AM; Prigitano A; Vidal-García M; Marcos-Arias C; Guridi A; Sanchez-Reus F; Machuca-Bárcena J; Rodríguez-Iglesias MA; Martín-Mazuelos E; Castro-Méndez C; López-Soria L; Ruiz-Gaitán A; Fernandez-Rivero M; Lorenzo D; Capilla J; Rezusta A; Pemán J; Guarro J; Pereira J; Pais C; Romeo O; Ezpeleta G; Jauregizar N; Angulo D; Eraso E
    Front Cell Infect Microbiol; 2022; 12():906563. PubMed ID: 35651755
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole.
    Pfaller MA; Diekema DJ; Messer SA; Boyken L; Huynh H; Hollis RJ
    J Clin Microbiol; 2002 May; 40(5):1694-7. PubMed ID: 11980944
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.
    Pfaller MA; Espinel-Ingroff A; Jones RN
    J Clin Microbiol; 2004 Oct; 42(10):4577-80. PubMed ID: 15472311
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicans.
    Nussbaumer-Pröll A; Matzneller P; Eberl S; Zeitlinger M
    Eur J Clin Microbiol Infect Dis; 2024 May; 43(5):927-936. PubMed ID: 38483681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.